SCA
SWTX

Snowden Capital Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Snowden Capital Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,115
Closed -$491K – 1264
2025
Q1 		$491K Sell
11,115
-339
-3% -$15.6K 0.02% 748
2024
Q4 		$414K Buy
11,454
+98
+0.9% +$3.42K 0.01% 849
2024
Q3 		$364K Buy
11,356
+346
+3% +$12.9K 0.01% 911
2024
Q2 		$415K Buy
11,010
+3,735
+51% +$157K 0.01% 837
2024
Q1 		$358K Sell
7,275
-275
-4% -$12.7K 0.01% 900
2023
Q4 		$276K Buy
+7,550
New +$197K 0.01% 931
2023
Q3 		– Sell
-7,898
Closed -$207K – 1186
2023
Q2 		$207K Buy
+7,898
New +$208K 0.01% 1091

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Snowden Capital Advisors's SWTX Position: Q2 2025 in Review

Snowden Capital Advisors sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 11,115 shares — an estimated $491K sold.

Snowden Capital Advisors first reported a position in SWTX in Q2 2023 and held it in 7 quarters. The position peaked at $491K in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Snowden Capital Advisors reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Snowden Capital Advisors sold 11,115 SpringWorks Therapeutics shares in Q2 2025, an estimated $491K.
  • Snowden Capital Advisors first reported a position in SpringWorks Therapeutics in Q2 2023 and held it in 7 quarters.
  • Snowden Capital Advisors's SpringWorks Therapeutics position peaked at $491K in Q1 2025.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Snowden Capital Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.